Cargando…

Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells

AIM: Visceral obesity is a key risk factor in the development of oesophagogastric junctional adenocarcinoma (OGJ), predominantly via generation of systemic low grade inflammation. Obesity-induced inflammation promotes resistance to current standards of care, enhancing tumour cell growth and survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Davern, Maria, Bracken-Clarke, Dara, Donlon, Noel E., Sheppard, Andrew D., Connell, Fiona O’, Heeran, Aisling B., Majcher, Klaudia, Conroy, Melissa J., Mylod, Eimear, Butler, Christine, Donohoe, Claire, Donnell, Dearbhaile O’, Lowery, Maeve, Bhardwaj, Anshul, Ravi, Narayanasamy, Melo, Ashanty A., Sullivan, Jacintha O’, Reynolds, John V., Lysaght, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356656/
https://www.ncbi.nlm.nih.gov/pubmed/36790524
http://dx.doi.org/10.1007/s00432-023-04620-6
_version_ 1785075325941579776
author Davern, Maria
Bracken-Clarke, Dara
Donlon, Noel E.
Sheppard, Andrew D.
Connell, Fiona O’
Heeran, Aisling B.
Majcher, Klaudia
Conroy, Melissa J.
Mylod, Eimear
Butler, Christine
Donohoe, Claire
Donnell, Dearbhaile O’
Lowery, Maeve
Bhardwaj, Anshul
Ravi, Narayanasamy
Melo, Ashanty A.
Sullivan, Jacintha O’
Reynolds, John V.
Lysaght, Joanne
author_facet Davern, Maria
Bracken-Clarke, Dara
Donlon, Noel E.
Sheppard, Andrew D.
Connell, Fiona O’
Heeran, Aisling B.
Majcher, Klaudia
Conroy, Melissa J.
Mylod, Eimear
Butler, Christine
Donohoe, Claire
Donnell, Dearbhaile O’
Lowery, Maeve
Bhardwaj, Anshul
Ravi, Narayanasamy
Melo, Ashanty A.
Sullivan, Jacintha O’
Reynolds, John V.
Lysaght, Joanne
author_sort Davern, Maria
collection PubMed
description AIM: Visceral obesity is a key risk factor in the development of oesophagogastric junctional adenocarcinoma (OGJ), predominantly via generation of systemic low grade inflammation. Obesity-induced inflammation promotes resistance to current standards of care, enhancing tumour cell growth and survival. This study investigates the effect of the visceral adipose tissue secretome from OGJ patients with early versus advanced tumours on T-cell immunity and the role of immune checkpoint blockade in enhancing anti-tumour immunity. METHODS AND RESULTS: Visceral adipose conditioned media (ACM) from both early and late-stage OGJ patients significantly altered T cell activation status, upregulating co-stimulatory marker CD27 on T cells. ACM from both early and late-stage OGJ patients significantly altered immune checkpoint expression profiles downregulating immune checkpoints (ICs) on the surface of dual Th1/17-like and Th17-like cells and upregulating ICs on the surface of Th1-like cells and Treg cells. ACM derived from early-stage OGJ patients but not late-stage OGJ patients increased IFN-γ production by T cells. The addition of immune checkpoint blockers (ICBs) did not increase IFN-γ production by T cells in the presence of late-stage ACM, collectively highlighting the dichotomous immunostimulatory effect of early-stage ACM and immune-inhibitory effect of late-stage ACM. Interestingly, ACM from early-stage OGJ patients was more pro-inflammatory than ACM from late-stage patients, reflected by decreased levels of IL-17A/F, TNF-α, IL-1RA and IL-5. CONCLUSION: The ACM-induced upregulation of ICs on T cells highlights a therapeutic vulnerability that could be exploited by ICBs to harness anti-cancer immunity and improve clinical outcomes for OGJ patients. GRAPHICAL ABSTRACT: Schematic workflow – (A) visceral adipose tissue was taken from OAC patients at time of surgery and cultured for 72 h in media. (B) The harvested ACM was co-cultured with healthy donor PBMCs that were concurrently activated with anti-CD3/28 for 48 h and T cell immunophenotyping was carried out by flow cytometry. Key findings – (A) Early and late stage ACM enhanced a Th1-like phenotype and upregulated CTLA-4 on Th1-like cells. A Th17-like phenotype was also enhanced in addition with a Treg-like phenotype. CTLA-4 and PD-L1 were upregulated on the surface of Treg-like cells. (B) ICB-attenuated IL-17 production by T cells. However, ACM attenuated ICB-mediated reduction in IL-10 production by T cells. Higher levels of pro-inflammatory factors were found in early stage ACM compared with late stage ACM. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-04620-6.
format Online
Article
Text
id pubmed-10356656
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103566562023-07-21 Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells Davern, Maria Bracken-Clarke, Dara Donlon, Noel E. Sheppard, Andrew D. Connell, Fiona O’ Heeran, Aisling B. Majcher, Klaudia Conroy, Melissa J. Mylod, Eimear Butler, Christine Donohoe, Claire Donnell, Dearbhaile O’ Lowery, Maeve Bhardwaj, Anshul Ravi, Narayanasamy Melo, Ashanty A. Sullivan, Jacintha O’ Reynolds, John V. Lysaght, Joanne J Cancer Res Clin Oncol Research AIM: Visceral obesity is a key risk factor in the development of oesophagogastric junctional adenocarcinoma (OGJ), predominantly via generation of systemic low grade inflammation. Obesity-induced inflammation promotes resistance to current standards of care, enhancing tumour cell growth and survival. This study investigates the effect of the visceral adipose tissue secretome from OGJ patients with early versus advanced tumours on T-cell immunity and the role of immune checkpoint blockade in enhancing anti-tumour immunity. METHODS AND RESULTS: Visceral adipose conditioned media (ACM) from both early and late-stage OGJ patients significantly altered T cell activation status, upregulating co-stimulatory marker CD27 on T cells. ACM from both early and late-stage OGJ patients significantly altered immune checkpoint expression profiles downregulating immune checkpoints (ICs) on the surface of dual Th1/17-like and Th17-like cells and upregulating ICs on the surface of Th1-like cells and Treg cells. ACM derived from early-stage OGJ patients but not late-stage OGJ patients increased IFN-γ production by T cells. The addition of immune checkpoint blockers (ICBs) did not increase IFN-γ production by T cells in the presence of late-stage ACM, collectively highlighting the dichotomous immunostimulatory effect of early-stage ACM and immune-inhibitory effect of late-stage ACM. Interestingly, ACM from early-stage OGJ patients was more pro-inflammatory than ACM from late-stage patients, reflected by decreased levels of IL-17A/F, TNF-α, IL-1RA and IL-5. CONCLUSION: The ACM-induced upregulation of ICs on T cells highlights a therapeutic vulnerability that could be exploited by ICBs to harness anti-cancer immunity and improve clinical outcomes for OGJ patients. GRAPHICAL ABSTRACT: Schematic workflow – (A) visceral adipose tissue was taken from OAC patients at time of surgery and cultured for 72 h in media. (B) The harvested ACM was co-cultured with healthy donor PBMCs that were concurrently activated with anti-CD3/28 for 48 h and T cell immunophenotyping was carried out by flow cytometry. Key findings – (A) Early and late stage ACM enhanced a Th1-like phenotype and upregulated CTLA-4 on Th1-like cells. A Th17-like phenotype was also enhanced in addition with a Treg-like phenotype. CTLA-4 and PD-L1 were upregulated on the surface of Treg-like cells. (B) ICB-attenuated IL-17 production by T cells. However, ACM attenuated ICB-mediated reduction in IL-10 production by T cells. Higher levels of pro-inflammatory factors were found in early stage ACM compared with late stage ACM. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-04620-6. Springer Berlin Heidelberg 2023-02-15 2023 /pmc/articles/PMC10356656/ /pubmed/36790524 http://dx.doi.org/10.1007/s00432-023-04620-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Davern, Maria
Bracken-Clarke, Dara
Donlon, Noel E.
Sheppard, Andrew D.
Connell, Fiona O’
Heeran, Aisling B.
Majcher, Klaudia
Conroy, Melissa J.
Mylod, Eimear
Butler, Christine
Donohoe, Claire
Donnell, Dearbhaile O’
Lowery, Maeve
Bhardwaj, Anshul
Ravi, Narayanasamy
Melo, Ashanty A.
Sullivan, Jacintha O’
Reynolds, John V.
Lysaght, Joanne
Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells
title Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells
title_full Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells
title_fullStr Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells
title_full_unstemmed Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells
title_short Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells
title_sort visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory t cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356656/
https://www.ncbi.nlm.nih.gov/pubmed/36790524
http://dx.doi.org/10.1007/s00432-023-04620-6
work_keys_str_mv AT davernmaria visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT brackenclarkedara visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT donlonnoele visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT sheppardandrewd visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT connellfionao visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT heeranaislingb visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT majcherklaudia visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT conroymelissaj visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT mylodeimear visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT butlerchristine visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT donohoeclaire visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT donnelldearbhaileo visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT lowerymaeve visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT bhardwajanshul visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT ravinarayanasamy visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT meloashantya visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT sullivanjacinthao visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT reynoldsjohnv visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells
AT lysaghtjoanne visceraladiposetissuesecretomefromearlyandlatestageoesophagealcancerpatientsdifferentiallyaffectseffectorandregulatorytcells